December 15, 2020
Weil is advising Eli Lilly and Company in its pending $1 billion acquisition of Prevail Therapeutics Inc., a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The transaction is expected to close in the first quarter of 2021, subject to customary closing conditions.
The Weil team advising Eli Lilly is led by Mergers & Acquisitions partner Raymond Gietz and includes Mergers & Acquisitions partner Matthew Gilroy and Mergers & Acquisitions associates Dov Kogen, Bilal Chaudhry and Tom Tsatsis. The team also includes Technology & IP Transactions partner Jeffrey Osterman; Technology & IP Transactions counsel Marisa Geiger; Technology & IP Transactions associate Kane Wishart; Executive Compensation & Benefits partner Amy Rubin; Executive Compensation & Benefits associate Tricia Walsh; Tax partner Helyn Goldstein; and Tax counsel Eric Remijan.